Ann Thornton
Analyst · Sidoti
Thanks, Russell. Our financial results were strong once again in the second quarter. Organic sales were up 1.6%. And as Russell just mentioned, this was our 20th consecutive quarter of organic sales growth as a company, which was led by the top line performance in our Americas and Asia region. The Americas and Asia grew 3.1% organically, which was partially offset by a slight organic decline of 1.1% in the Europe and Australia region. We also reported strong growth in our adjusted pretax income as well as our adjusted diluted earnings per share in the quarter, while funding a significant increase in research and development. And we finished the quarter in a net cash position, which allows us to continue to invest in both organic opportunities and strategic acquisitions to continue to drive shareholder value into the future. Slide #4 details our quarterly sales trends. Organic sales grew 1.6% this quarter. Acquisitions added 2.3% and foreign currency translation increased sales by 3.8% for total sales growth of 7.7%. Slide #5 details our quarterly gross margin trending. Our gross profit margin was 50.6% this quarter compared to 49.3% in the second quarter of last year. Last year, we took actions to streamline our cost structure, and we closed manufacturing facilities in Beijing, China and Buffalo, New York, and we reorganized our overhead structure in Europe. Adjusting for the onetime charges in gross margin in last year's Q2, our gross margin -- gross profit margin would have been 49.8% in last year's second quarter. You can see the gross margin benefit from cost reduction actions in our results, along with our sales growth coming from our highly engineered products, both of which led to the improvement in gross profit margin from 49.8% last year to 50.6% this year. Turning to Slide #6. This details our SG&A expense trending. SG&A was $107.9 million this quarter compared to $105.9 million in the second quarter last year. As a percent of sales, SG&A decreased to 28.1% of sales 29.7% last year. If you exclude amortization expense from the current and prior year, as well as the facility closure and other reorganization costs that we incurred last year then SG&A was 26.7% of sales this quarter compared to 27.3% of sales last quarter. A decline of 60 basis points. We're seeing the benefits of our facility closure and other cost structure actions that we took last year, while we continue to invest in growth through targeted additions to our sales force as well as expanding in certain geographies. Moving to Slide #7. This details the trending of our investments in research and development. We continue to increase our investment in new products within our organic business with products like [ i-4311 ] that Russell just described as well as products from our acquisitions from last year. R&D expense was $24.3 million or 6.3% of sales this quarter which was an increase from $18.7 million or 5.2% of sales in last year's second quarter. We funded a nearly 30% increase in R&D in the quarter and still improved profitability. For the second half of this year, we do expect R&D as a percent of sales to be around 5.5% of sales, which would put us slightly below 6% of sales for the full fiscal year 2026. Slide #8 shows the trending of our pretax earnings. Pretax earnings on a GAAP basis increased 19.1% from $52 million to $62 million in the quarter. If you exclude amortization from both periods and exclude the facility closure and other reorganization charges we incurred last year, pretax earnings increased 7.7% from $62.4 million to $67.2 million. Turning to Slide #9. This details the trending of our net income and earnings per share. Our net income increased 19.1% from $40.3 million to $48.1 million. Excluding amortization from both periods as well as the facility closure and other reorganization charges from last year, net income increased 8% from $48.1 million to $52 million. GAAP diluted earnings per share was $1.01 compared to $0.83 last year. Excluding amortization from both periods and the facility closure and other reorg charges from last year, our adjusted diluted earnings per share grew to $1.09 this year from $1 last year, an increase of 9%. Our results continue to benefit from sales growth in our highest gross margin products as well as from the cost reduction actions that we took last year in certain areas of our business. Moving to Slide #10. This details our cash generation. Operating cash flow increased 34.7% to $53.3 million in the second quarter of this year compared to $39.6 million in the second quarter of last year. And free cash flow increased 30.5% to $42.3 million in Q2 of this year compared to $32.5 million in last year's Q2. Year-to-date, our cash flow from operating activities is up nearly 38% versus last year, which demonstrates our high-quality earnings and our consistent focus on cash-based decision-making. Slide #11 outlines the impact that our cash generation has had on our balance sheet. As of January 31, we were in a net cash position of $97.8 million. Our approach to capital allocation is consistent, and that is to always fund organic sales growth and efficiency opportunities. This includes investing in new product development, sales-generating resources, capability-enhancing CapEx and improvements in automation. We have the ability to invest throughout the economic cycle so that we're always positioned to grow the top line and our profitability. And we're focused on consistently increasing our dividends. At the beginning of this fiscal year, we announced our 40th consecutive annual dividend increase, which was a very exciting milestone for us as a company. From here, we're disciplined and opportunistic in our approach to both acquisitions and share buybacks. We're focused on identifying acquisitions with clear synergies, and we have the financial strength to do all of this to fund our organic business, our dividend, M&A opportunities and share buybacks. So far this year, we've purchased 121,000 shares for $9 million, which works out to an average price of $74.23 per share. Moving to Slide #12. This details our fiscal 2026 guidance. We are increasing the bottom end of our full year fiscal 2026 previously announced adjusted diluted EPS guidance range from $4.90 to $5.15 per share to $4.95 to $5.15 per share. And we are increasing the bottom end of our full year GAAP EPS guidance range from $4.57 to $4.82 per share to $4.62 to $4.82 per share. Our adjusted diluted EPS guidance range represents a range of growth of between 7.6% to 12% compared to 2025. We expect organic sales growth in the low single-digit percentages for the year ending July 31, 2026. Other elements of our guidance include depreciation and amortization expense of approximately $44 million, capital expenditures of approximately $45 million and a full year income tax rate of approximately 21%. Our income tax rate generally tends to be slightly lower in the fourth quarter compared to our full year expectation which is based upon our historical profit mix and the expected timing of other discrete adjustments. Potential risks to our guidance, among others, include potential strengthening of the U.S. dollar, inflationary pressures that were unable to offset in a timely enough manner or an overall slowdown in economic activity. Now I'll turn it back over to Russell to cover our regional results and to provide some closing thoughts before Q&A. Russell?